

Please type a plus sign (+) inside this box → **+**

Op 16531 Box Seq

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/667,380
		Filing Date	Sep 22, 2000
		First Named Inventor	Donoho, Gregory
		Group Art Unit	1653
		Examiner Name	R. Mitra
Total Number of Pages in This Submission	5	Attorney Docket Number	LEX-0042-US

RECEIVED
 APR 22 2002
 TECH CENTER 1602200

#10
490
5/12

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Response to Notice to Compily - Copy of Notice to Compily - Verified Statement regarding Sequence Listing - Sequence Listing in CRF on diskette
Remarks _____		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Lexicon Genetics Incorporated		
	Lance K. Ishimoto	Reg. No. 41,866	
Signature	<i>Lance K. Ishimoto by David W. Hubler</i> DAVID W. HUBLER REG. NO. 41,071		24231 PATENT TRADEMARK OFFICE
Date	April 9, 2002		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date: April 9, 2002			
Typed or printed name	Michelle Klein		
Signature			
Date	April 9, 2002		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Donoho *et al.*
 Application No.: 09/667,380
 Filed: September 22, 2000

Group Art Unit: 1653
 Examiner: R. Mitra

Title: Novel Human Protease Inhibitor-Like Proteins
 and Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0042-USA



24231

PATENT TRADEMARK OFFICE

**RESPONSE TO NOTICE TO COMPLY WITH
 REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

TECH CENTER 1600/2900

APR 22 2002

RECEIVED

Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("the Notice") mailed March 27, 2002, in connection with the above-identified application, Applicants submit herewith: (i) a Sequence Listing in computer readable form pursuant to 37 C.F.R. §1.821(e); and (ii) a Verified Statement Concerning Sequence Listing Under 37 C.F.R. § 1.821(f). Applicants respectfully request the entry of the computer readable form of the Sequence Listing into the file.

In the Notice, Applicants were additionally required to provide a substitute paper copy of the Sequence Listing. However, the Notice did not indicate that the paper copy of the Sequence Listing as originally filed was missing, and this was confirmed during a telephone conference between Applicants' representative Mrs. Michelle Klein and Patent Examiner Mitra on April 5, 2002. During the telephone conference, Patent Examiner Mitra indicated that a substitute paper copy of the Sequence Listing did not need to be filed if the CRF copy of the Sequence Listing is identical to the paper copy of the Sequence Listing as originally filed. Therefore, Applicants are providing herewith a CRF copy of the Sequence Listing, and a statement that the content of the original paper and computer readable copies of the Sequence Listing are the same.

Applicants believe that no fee is due in connection with this response.
However, the Commissioner is authorized to charge any required fee to Deposit
Account No. 50-0892.

Respectfully submitted,

April 9, 2002
Date

Lance K. Ishimoto by David W. Haber *DAVID W. HABER*
Lance K. Ishimoto *REG. NO. 41,071*
Reg. No. 41,866

LEXICON GENETICS INCORPORATED
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Notice to Comply

Application No.

09/667380

Examiner

Rita Mitra, Ph. D.

Applicant(s)

Donoho et al.

Art Unit

1653

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

